Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies
Frontiers in Immunology · 2023
DOI: 10.3389/fimmu.2023.1200652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2023. Verfasst von Abdennour Benloucif und 9 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France. Hauptthemen laut MEDLINE: Mesothelin, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique.
Abstract (Originalsprache)
Introduction
Mesothelin (MSLN) is overexpressed in a wide variety of cancers with few therapeutic options and has recently emerged as an attractive target for cancer therapy, with a large number of approaches currently under preclinical and clinical investigation. In this respect, developing mesothelin specific tracers as molecular companion tools for predicting patient eligibility, monitoring then response to mesothelin-targeting therapies, and tracking the evolution of the disease or for real-time visualisation of tumours during surgery is of growing importance.
Methods
We generated by phage display a nanobody (Nb S1) and used enzymatic approaches were used to site-directed conjugate Nb S1 with either ATTO 647N fluorochrome or NODAGA chelator for fluorescence and positron emission tomography imaging (PET) respectively.
Results
We demonstrated that Nb S1 displays a high apparent affinity and specificity for human mesothelin and demonstrated that the binding, although located in the membrane distal domain of mesothelin, is not impeded by the presence of MUC16, the only known ligand of mesothelin, nor by the therapeutic antibody amatuximab. In vivo experiments showed that both ATTO 647N and [ 68 Ga]Ga-NODAGA-S1 rapidly and specifically accumulated in mesothelin positive tumours compared to mesothelin negative tumours or irrelevant Nb with a high tumour/background ratio. The ex vivo biodistribution profile analysis also confirmed a significantly higher uptake of Nb S1 in MSLN-positive tumours than in MSLN low tumours.
Conclusion
We demonstrated for the first time the use of an anti-MSLN nanobody as PET radiotracer for same day imaging of MSLN + tumours, targeting an epitope compatible with the monitoring of amatuximab-based therapies and current SS1-derived-drug conjugates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
- Aix Marseille Univ, CNRS, Centre Européen de Recherche en Imagerie Medicale (CERIMED), Marseille, France.
- Aix-marseille University, INSERM, INRAE, Centre de recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France.
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, TrGET Preclinical Platform, Marseille, France.
Förderung
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
Zitieren
APA
Benloucif, A., Meyer, D., Balasse, L., Goubard, A., Danner, L., Bouhlel, A., Castellano, R., Guillet, B., Chames, P., & Kerfelec, B. (2023). Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1200652
Vancouver
Benloucif A, Meyer D, Balasse L, Goubard A, Danner L, Bouhlel A, et al. Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2023.1200652
BibTeX
@article{Benloucif2023,
author = {Benloucif, Abdennour and Meyer, Damien and Balasse, Laure and Goubard, Armelle and Danner, Lucile and Bouhlel, Ahlem and Castellano, Rémy and Guillet, Benjamin and Chames, Patrick and Kerfelec, Brigitte},
title = {Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies},
journal = {Frontiers in Immunology},
year = {2023},
doi = {10.3389/fimmu.2023.1200652}
}
EUVIMED